problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201258341-45problendo-4688Research ArticleСтатьиArticlesЭффективность применения вилдаглиптина у пациентов с коморбидной патологиейThe efficacy of application of vildagliptin in the patints presenting with co-morbid pathologyVertkinA Lkafedrakf@mail.ruMagomedovaA Iu-MychkaV B-ProkhorovaIu V-NosovaA V-201215062012583ТОМ 58, №3 (2012)4145Copyright © Vertkin A.L., Magomedova A.I., Mychka V.B., Prokhorova I.V., Nosova A.V., 20122012Vertkin A.L., Magomedova A.I., Mychka V.B., Prokhorova I.V., Nosova A.V.Vertkin A.L., Magomedova A.I., Mychka V.B., Prokhorova I.V., Nosova A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4688

Нередко больные сахарным диабетом 2-го типа (СД2) имеют сопутствующие заболевания сердечно-сосудистой, дыхательной, пищеварительной и мочеполовой систем, что затрудняет выбор оптимальной сахарснижающей терапии. В такой ситуации наиболее естественным и эффективным методом сахарснижающей терапии является назначение инсулина. Однако избыточные его дозы нередко обусловливают гипогликемию и прибавку массы тела. Гипогликемия создает наибольший барьер для оптимального гликемического контроля, особенно у лиц старшей возрастной группы, которые слабее реагируют на нее. В проведенном авторами исследовании прием вилдаглиптина в сочетании с инсулином позволял добиться выраженного улучшения показателей углеводного и липидного обмена без повышения массы тела и с минимальным риском развития гипогликемий и сердечно-сосудистых заболеваний (осложнений).

The patients presenting with type 2 diabetes mellitus (DM2) not infrequently have concomitant diseases of the cardiovascular, respiratory, digestive, and urogenital systems which hampers the choice of optimal hypoglycemic therapy. The prescription of insulin injections appears to be the most natural and efficacious modality of such therapy. However, excessive doses of insulin are known to cause hypoglycemia and body weight increment. Hypoglycemia interferes with the optimal control of the diabetic patients' conditions especially in those of advanced age who may poorly respond to the treatment. In the present study, the intake of vildagliptin in combination with insulin administration resulted in the significant improvement of the characteristics of carbohydrate and lipid metabolism in the absence of overweight, with the minimal risk of hypoglycemia and cardiovascular diseases (complications).

коморбидностьсахарный диабет 2-го типагипогликемиявилдаглиптинco-morbiditytype 2 diabetes mellitushypoglycemiavildagliptinReferencesДедов И.И., Шестакова М.В. Сахарный диабет в пожилом возрасте: диагностика, клиника, лечение. Практическое руководство для врачей. М 2011.Дедов И.И., Шестакова М.В. Сахарный диабет в пожилом возрасте: диагностика, клиника, лечение. Практическое руководство для врачей. М 2011.Аметов А.С., Карпова Е.В. Инкретиномиметики - новый этап в лечении сахарного диабета 2-го типа. Эндокринология 2010; 23: 1410-1415.Аметов А.С., Карпова Е.В. Инкретиномиметики - новый этап в лечении сахарного диабета 2-го типа. Эндокринология 2010; 23: 1410-1415.Drucken D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.Drucken D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.Романцова Т.И. Ингибитор дипептидилпептидазы-4-ситаглип­тин: новые возможности терапии сахарного диабета 2-го типа. Ожирение и метаболизм 2006; 4: 9.Романцова Т.И. Ингибитор дипептидилпептидазы-4-ситаглип­тин: новые возможности терапии сахарного диабета 2-го типа. Ожирение и метаболизм 2006; 4: 9.Maegawa H. Sitagliptin added to ongoing treatment with pioglitazone study up-to 52 weeks in Japanese patients with T2DM. EASD Poster 2008.Maegawa H. Sitagliptin added to ongoing treatment with pioglitazone study up-to 52 weeks in Japanese patients with T2DM. EASD Poster 2008.Fonseca V., Dejager S., Albrecht S. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: Suppl 1: A111.Fonseca V., Dejager S., Albrecht S. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006; 55: Suppl 1: A111.Toft-Nielsen M.B. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.Toft-Nielsen M.B. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.Vilsboll T. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119.Vilsboll T. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119.Knop F.K. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009; 52: 2270-2276.Knop F.K. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009; 52: 2270-2276.Kieffer T.J. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.Kieffer T.J. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.Kieffer T.J. Endocrinilogy 1995; 136: 3585-3596.Kieffer T.J. Endocrinilogy 1995; 136: 3585-3596.Deacon C.F. J Clin Endocrinol Metab 1995; 80: 952-957.Deacon C.F. J Clin Endocrinol Metab 1995; 80: 952-957.Rosenstock J. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: double-blind, randomized trial. Diabetes Care 2007; 30: 2: 217-223.Rosenstock J. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: double-blind, randomized trial. Diabetes Care 2007; 30: 2: 217-223.Duttaroy A. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis ecreases apoptosis. Poster №572 presented at ADA 2005.Duttaroy A. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis ecreases apoptosis. Poster №572 presented at ADA 2005.Bosi E. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.Bosi E. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.Boschmann M. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 846-852.Boschmann M. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 846-852.Nikolaidis L., Mankad S., Sokos G. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulartion 2004; 109: 962-965.Nikolaidis L., Mankad S., Sokos G. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulartion 2004; 109: 962-965.Ban K. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 2008; 117: 2340-2350.Ban K. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 2008; 117: 2340-2350.Nathewani A. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. ADA 2006; 474.Nathewani A. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. ADA 2006; 474.Diess D., Bosi E. Improved glycemic control in poorly controlled patients with type 1diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730-2732.Diess D., Bosi E. Improved glycemic control in poorly controlled patients with type 1diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730-2732.Matikainen N. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 9: 2049-2057.Matikainen N. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 9: 2049-2057.Ligueros-Saylan M., Schweizer A., Dickinson S., Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. EASD 2009.Ligueros-Saylan M., Schweizer A., Dickinson S., Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. EASD 2009.He Y.-L. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131-1138.He Y.-L. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131-1138.Ayalasomayajula S.P., Dole K. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007; 23: 12: 2913-2920.Ayalasomayajula S.P., Dole K. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007; 23: 12: 2913-2920.

The authors declare that there are no conflicts of interest present.